• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Can We Conquer Advanced Head and Neck Cancer? Current Status and Future Directions.我们能攻克晚期头颈癌吗？现状与未来方向
Clin Exp Otorhinolaryngol. 2021 May;14(2):145-146. doi: 10.21053/ceo.2021.00458. Epub 2021 Apr 30.
2
Workshop report: organ preservation strategies in advanced head and neck cancer--current status and future directions.研讨会报告：晚期头颈癌的器官保存策略——现状与未来方向
Head Neck. 1999 Dec;21(8):689-93. doi: 10.1002/(sici)1097-0347(199912)21:8<689::aid-hed2>3.0.co;2-0.
3
Future treatment directions for HPV-associated head and neck cancer based on radiobiological rationale and current clinical evidence.基于放射生物学原理和当前临床证据的人乳头瘤病毒相关头颈癌的未来治疗方向
Crit Rev Oncol Hematol. 2016 Jul;103:27-36. doi: 10.1016/j.critrevonc.2016.05.002. Epub 2016 May 11.
4
Current status and future directions in induction chemotherapy for head and neck cancer.头颈部癌症诱导化疗的现状与未来方向。
Crit Rev Oncol Hematol. 2013 Oct;88(1):57-74. doi: 10.1016/j.critrevonc.2013.03.001. Epub 2013 Mar 27.
5
Adjuvant chemotherapy of head and neck cancer: the past, the present, and the future.头颈癌的辅助化疗：过去、现在与未来。
Semin Oncol. 1988 Jun;15(3 Suppl 3):45-59.
6
Chemotherapy with Platinum Compounds: Current Status and Future Directions. Volume 3: Dosing, Head and Neck Cancer, Genitourinary Cancer, Pediatric Cancer, Tumor of Unknown Origin, Dose Intensity, Future Directions. Kona, Hawaii, February 24-28, 1993.铂类化合物化疗：现状与未来方向。第3卷：给药、头颈癌、泌尿生殖系统癌、儿科癌症、原发灶不明肿瘤、剂量强度、未来方向。夏威夷科纳，1993年2月24日至28日。
Semin Oncol. 1994 Oct;21(5 Suppl 12):1-118.
7
Assessment and measurement of head and neck lymphedema: state-of-the-science and future directions.头颈部淋巴水肿的评估与测量：科学现状与未来方向
Oral Oncol. 2015 May;51(5):431-7. doi: 10.1016/j.oraloncology.2015.01.005. Epub 2015 Feb 20.
8
PET-Computed Tomography in Head and Neck Cancer: Current Evidence and Future Directions.头颈部癌的正电子发射断层扫描-计算机断层扫描：当前证据与未来方向
Magn Reson Imaging Clin N Am. 2018 Feb;26(1):37-49. doi: 10.1016/j.mric.2017.08.003. Epub 2017 Oct 12.
9
Neoadjuvant chemotherapy for locally advanced squamous cancers of the head and neck: current status and future prospects.局部晚期头颈部鳞状细胞癌的新辅助化疗：现状与未来展望
Curr Opin Oncol. 2009 May;21(3):218-23. doi: 10.1097/cco.0b013e328329abe5.
10
Neck dissection: current concepts and future directions.颈部淋巴结清扫术：当前概念与未来方向。
Surg Oncol Clin N Am. 2004 Jan;13(1):151-66. doi: 10.1016/S1055-3207(03)00119-4.

引用本文的文献

1
Antioxidant, cytotoxic, anti-migratory, and pro-apoptotic effects of Bolanthus turcicus extracts on head and neck cancer cells.土耳其蓝刺头提取物对头颈部癌细胞的抗氧化、细胞毒性、抗迁移和促凋亡作用。
Mol Biol Rep. 2024 Oct 30;51(1):1104. doi: 10.1007/s11033-024-09994-5.

本文引用的文献

1
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
2
Survival Benefits From Surgery for Stage IVa Head and Neck Squamous Cell Carcinoma: A Multi-institutional Analysis of 1,033 Cases.IVa期头颈部鳞状细胞癌手术的生存获益：1033例多机构分析
Clin Exp Otorhinolaryngol. 2021 May;14(2):225-234. doi: 10.21053/ceo.2020.01732. Epub 2020 Sep 25.
3
Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01).局部晚期头颈部鳞状细胞癌的治疗策略和结果：一项全国性回顾性队列研究（KCSG HN13-01）。
BMC Cancer. 2020 Aug 27;20(1):813. doi: 10.1186/s12885-020-07297-z.
4
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.帕博利珠单抗单药或联合化疗对比西妥昔单抗联合化疗用于治疗复发性或转移性头颈部鳞状细胞癌（KEYNOTE-048）：一项随机、开放标签、III 期研究。
Lancet. 2019 Nov 23;394(10212):1915-1928. doi: 10.1016/S0140-6736(19)32591-7. Epub 2019 Nov 1.
5
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.纳武利尤单抗对比研究者选择的标准单药疗法用于复发性或转移性头颈部鳞状细胞癌（CheckMate 141）：一项随机3期试验的健康相关生活质量结果
Lancet Oncol. 2017 Aug;18(8):1104-1115. doi: 10.1016/S1470-2045(17)30421-7. Epub 2017 Jun 23.
6
Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis.20 世纪末至 21 世纪初头颈部癌症生存率的变化：一项时期分析。
Oncologist. 2010;15(9):994-1001. doi: 10.1634/theoncologist.2009-0289. Epub 2010 Aug 26.
7
Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial.西妥昔单抗治疗转移性或复发性头颈癌：EXTREME试验
Expert Rev Anticancer Ther. 2009 Oct;9(10):1421-8. doi: 10.1586/era.09.113.

Can We Conquer Advanced Head and Neck Cancer? Current Status and Future Directions.

作者信息

Won Ho-Ryun, Koo Bon Seok

机构信息

Department of Otolaryngology-Head and Neck Surgery, Chungnam National University College of Medicine, Daejeon, Korea.

出版信息

Clin Exp Otorhinolaryngol. 2021 May;14(2):145-146. doi: 10.21053/ceo.2021.00458. Epub 2021 Apr 30.

DOI:10.21053/ceo.2021.00458
PMID:33971695
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8111398/
Abstract
摘要